Clinical Trials Directory

Trials / Unknown

UnknownNCT05579301

Study of Comprehensive ANd Multimodal Marker-based Cohort of Progressive Supranuclear Palsy(PSP)

Biomarker Development for Progressive Supranuclear Palsy Through Multi-dimensional SNU-PSP Cohort Database

Status
Unknown
Phase
Study type
Observational
Enrollment
130 (estimated)
Sponsor
Seoul National University Hospital · Academic / Other
Sex
All
Age
50 Years – 80 Years
Healthy volunteers
Accepted

Summary

The purpose of this cohort study is to develop a reliable biomarker in progressive nuclear palsy (PSP).

Detailed description

Progressive supranuclear palsy is a rapidly progressive neurodegenerative disease without a cure. Thus, the development of a biomarker that reflects and monitors disease severity in PSP is critical for early diagnosis and performing a successful clinical trial. Thus, we will prospectively recruit patients with PSP and collect comprehensive clinical, imaging and blood biomarkers at baseline with longitudinal follow-up for 1 year.

Conditions

Timeline

Start date
2021-12-19
Primary completion
2024-12-19
Completion
2025-02-28
First posted
2022-10-13
Last updated
2022-10-13

Locations

2 sites across 1 country: South Korea

Source: ClinicalTrials.gov record NCT05579301. Inclusion in this directory is not an endorsement.

Study of Comprehensive ANd Multimodal Marker-based Cohort of Progressive Supranuclear Palsy(PSP) (NCT05579301) · Clinical Trials Directory